IP Library Patent Application 11282853
Patent Application
App. No. 11/282,853

Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/282,853
Abstract

Methods of using inhibitors of the CD2/LFA-3 interaction-in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.

Claims (10)

1 - 74 . (canceled)

75 . An anti-LFA-3 antibody, wherein the antibody is a 1E6 antibody, an HC-1B11 antibody, a 7A6 antibody, or an 8B8 antibody.

76 . The antibody of claim 75 , wherein the antibody is a monoclonal antibody.

77 . The antibody of claim 75 , wherein the antibody is produced by a hybridoma having an ATCC accession number selected from the group consisting of HB10693, HB 10694, HB 10695 and HB 10696.

78 . An anti-LFA-3 antibody having the sequence of an antibody produced by a hybridoma having an ATCC accession number selected from the group consisting of HB 10693, HB10694, HB10695 and HB10696.

79 . A recombinant, chimeric, or humanized antibody derived from the antibody of any one of claims 75 to 78 .

80 . An antigen-binding portion of the antibody of any one of claims 75 to 78 .

81 . The antigen-binding portion of claim 80 , wherein the antigen-binding portion is an Fab fragment, an Fab′ fragment, an F(ab′) 2 fragment, an F(v) fragment, a heavy chain monomer, a heavy chain dimer, a light chain monomer, a light chain dimer, or a dimer consisting of one heavy chain and one light chain.

82 . An antigen-binding portion of the antibody of claim 79 .

83 . The antigen-binding portion of claim 82 , wherein the antigen-binding portion is an Fab fragment, an Fab′ fragment, an F(ab′) 2 fragment, an F(v) fragment, a heavy chain monomer, a heavy chain dimer, a light chain monomer, a light chain dimer, or a dimer consisting of one heavy chain and one light chain.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2006
From: BIOGEN IDEC MA INC.
To: ASTELLAS US LLC
Reel/Frame 017596/0467 →
CHANGE OF NAME Recorded Mar 29, 2006
From: BIOGEN, INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 017468/0289 →